Oncology | Approved Drugs in UNITED KINGDOM

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Selumetinib Granted Orphan Drug Designation in Japan for Neurofibromatosis Type 1

Lead Product(s): Selumetinib

Therapeutic Area: Oncology Product Name: Koselugo

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

In the SPRINT trial, selumetinib was shown to reduce the size of these tumours in children. Phase I/II SPRINT Stratum 1 trial showed an overall response rate of 66% in paediatric patients with NF1 PN when treated with selumetinib as a twice-daily oral monotherapy.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukaemia in Two Trials

Lead Product(s): Acalabrutinib

Therapeutic Area: Oncology Product Name: Calquence

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

Lead Product(s): Olaparib,Bevacizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 08, 2020

Details:

U.S. FDA has approved LYNPARZA in combination with bevacizumab as a first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Porton Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Porton Biopharma Limited Licenses Erwinase® to Clinigen

Lead Product(s): Asparaginase

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Clinigen Group

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 16, 2020

Details:

Under the terms of the agreement, Clinigen will distribute Erwinase®/ Erwinaze®, the Porton's life-saving treatment for acute lymphoblastic leukaemia.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease

Lead Product(s): Selumetinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 13, 2020

Details:

The approval was based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase II SPRINT Stratum 1 trial.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Tagrisso Phase III ADAURA Trial will be Unblinded Early After Overwhelming Efficacy in the Adjuvant Treatment

Lead Product(s): Osimertinib Mesylate

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 10, 2020

Details:

ADAURA is the first global trial for an EGFR inhibitor to show statistically significant and clinically meaningful benefit in adjuvant treatment of lung cancer.

Clinigen Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Clinigen signs agreement with Iovance Biotherapeutics to supply Proleukin® (aldesleukin) for use in Tumor Infiltrating Lymphocyte (TIL) Cli...

Lead Product(s): Aldesleukin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Iovance Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 14, 2020

Details:

Proleukin will be made available by Clinigen in bulk supply over the course of a two-year period, ensuring that Iovance has uninterrupted access to Proleukin to continue ongoing clinical trials.

Find

Find Approved Oncology Drugs in Clinical Development in UNITED KINGDOM

United Kingdom

Product Type

Companies

AstraZeneca PLC

Selumetinib Granted Orphan Drug Designation in Japan for Neurofibromatosis Type 1

AstraZeneca PLC

Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukaemia in Two Trials

AstraZeneca PLC

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

Porton Biopharma

Porton Biopharma Limited Licenses Erwinase® to Clinigen

AstraZeneca PLC

FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease

AstraZeneca PLC

Tagrisso Phase III ADAURA Trial will be Unblinded Early After Overwhelming Efficacy in the Adjuvant Treatment

Clinigen Group

Clinigen signs agreement with Iovance Biotherapeutics to supply Proleukin® (aldesleukin) for use in Tumor Infiltrating Lymphocyte (TIL) Cli...